Alexandra Heumber Perry: Rare Diseases as a Measure of Equity and Multilateralism in Global Health
Alexandra Heumber Perry, Chief Executive Officer at Rare Diseases International, shared a post on LinkedIn:
”As the WHO Executive Board kicks off, global health governance once again finds itself at a crossroads. Decisions taken now will shape the future of global health architecture and determine whether we strengthen multilateralism or drift further toward fragmented, bilateral approaches.
This debate could not be more timely. Rare Disease Day month has just begun, and it coincides with an important milestone: one year ago, the World Health Organization Executive Board recommended the adoption of the first-ever WHO Resolution on Rare Diseases to the World Health Assembly.
That moment mattered – not only for the rare disease community, but for global health as a whole. It signaled that equity, inclusion, and solidarity still have a place at the heart of multilateral decision-making.
As we rethink global health architecture, a fundamental question remains: can we finally build systems that truly serve the most underserved? And can this moment of reform fulfil the core purpose of global health – to achieve equity, solidarity, and resilience across all populations?
Through ongoing conversations with colleagues and health leaders, I’ve been reflecting on this transition. Funding cuts, shifting priorities, and institutional reforms are forcing us to confront a deeper issue: what kind of health system are we rebuilding, and for whom?
Moving forward requires transversal approaches – breaking silos between diseases, sectors, and populations. Equity, data, and meaningful community engagement must underpin efforts to strengthen health systems. Integrated care pathways build resilience. Inclusive governance restores trust.
This is where rare diseases offer a powerful test – and a clear lesson. Rare diseases make inequities visible. They reveal gaps in data, access, financing, and governance. And they remind us that when systems are designed for those with the most complex needs, they become stronger for everyone.
Rare diseases have always been a precursor: if it works for people living with rare diseases, it works for everyone.
As global health governance is debated this week at the WHO Executive Board, rare diseases stand as a measure of our collective commitment to multilateralism, equity, and solidarity and a tangible way to turn global health transformation into reality.”
Stay updated with Hemostasis Today.
-
Mar 25, 2026, 16:00Randa Bascharon: When to Consider Wharton’s Jelly in Tendon, Ligament, and Joint Conditions
-
Mar 25, 2026, 15:56Boris Pasche: Karmanos Cancer Institute Leads Innovation in Cancer and Hematologic Disease Treatment
-
Mar 25, 2026, 15:52Indunil Karunarathna: Kawasaki Disease at the Intersection of Immunology, Cardiology, and Vascular Biology
-
Mar 25, 2026, 15:48Micah Grey: Reflecting on an Incredible Experience at the THSNA Congress
-
Mar 25, 2026, 15:45Christi Miller: Exploring Key Facts about Hemophilia During Bleeding Disorders Awareness Month
-
Mar 25, 2026, 15:44Stéphane Laurent: Why the Relationship Between AfSBT and ISBT Matters in Blood Management
-
Mar 25, 2026, 15:36Seema Dawood: EDTA-Induced Platelet Satellitism
-
Mar 25, 2026, 15:35ABO-Incompatible Transfusions and Severe Allergic Reactions – ISBT
-
Mar 25, 2026, 15:14Critical Gaps in AF Stroke Prevention – JTH